Concepedia

Author

Thomas Schaeffer

Bristol-Myers Squibb (United States)ORCID

Also Known As

T R Schaeffer, T. R. SCHAEFFER, T. R. Schaeffer, T. Schaeffer, T.R. Schaeffer, Thomas R. Schaeffer, Thomas Schaeffer

93

Publications

1.3K

Citations

18

H-Index

65

Concepts

All Affiliations

Bristol-Myers Squibb (United States)GlaxoSmithKline (United Kingdom)GlaxoSmithKline (United States)Bristol-Myers Squibb (Germany)Bristol-Myers Squibb (Sweden)
TS

About

Thomas Schaeffer is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

15

849

2

Natural Sciences

5

5

376

3

Engineering

1

1

20

4

Health Sciences

1

1

27

5

Public Health

1

1

96

Thomas Schaeffer

×

23

Publications

1.3K

Citations

18

H-Index

YearCitations

Dual Metalloprotease Inhibitors:  Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase

Jeffrey A. Robl, Chong‐Qing Sun, Jay Stevenson,

Journal of Medicinal Chemistry

1997

198

Antihypertensive activity in rats for SQ 14,225, an orally active inhibitor of angiotensin I-converting enzyme.

Robert J. Laffan, M.E. Goldberg, John P. High,

Journal of Pharmacology and Experimental Therapeutics

1978

173

Inhibition of Pressor Effects of Angiotensin I and Augmentation of Depressor Effects of Bradykinin by Synthetic Peptides

Sean Engel, Thomas Schaeffer, Barry Gold,

Experimental Biology and Medicine

1972

146

Comorbidity in patients with cancer: Prevalence and severity measured by cumulative illness rating scale

Ulrich Wedding, Bernd Roehrig, Almuth Klippstein,

Critical Reviews in Oncology/Hematology

2007

96

Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.

N. C. Trippodo, Jeffrey A. Robl, Magdi M. Asaad,

Journal of Pharmacology and Experimental Therapeutics

1995

84

Quinoxaline N-oxide containing potent angiotensin II receptor antagonists: synthesis, biological properties, and structure-activity relationships

Kyoung Soon Kim, Ligang Qian, J. Eileen Bird,

Journal of Medicinal Chemistry

1993

70

Effects of the Nonapeptide SQ 20881 on Blood Pressure of Rats with Experimental Renovascular Hypertension

Sean Engel, Thomas Schaeffer, Miranda Waugh,

Experimental Biology and Medicine

1973

64

Dual Metalloprotease Inhibitors. 6. Incorporation of Bicyclic and Substituted Monocyclic Azepinones as Dipeptide Surrogates in Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitors

Jeffrey A. Robl, Maria P. Cimarusti, Ligaya M. Simpkins,

Journal of Medicinal Chemistry

1996

60

SB 234551 selective ETA receptor antagonism: Perfusion/Diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection

Jeffrey J. Legos, Stephen C. Lenhard, Robin E. Haimbach,

Experimental Neurology

2008

47

Simultaneous assessment of left‐ventricular infarction size, function and tissue viability in a murine model of myocardial infarction by cardiac manganese‐enhanced magnetic resonance imaging (MEMRI)

Tom C. Hu, Weike Bao, Stephen C. Lenhard,

NMR in Biomedicine

2004

45

Page 1